Business Context and Reporting Period
This Form 8-K was filed by 180 Life Sciences Corp. (trading symbol: ATNF) on January 5, 2021. The report addresses a notice of delisting or failure to satisfy continued listing rules with the Nasdaq Stock Market LLC. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance issues rather than financial performance.
Material Changes Versus Prior Period
- Board Composition Changes: Effective December 17, 2020, Shoshana Shendelman, Ph.D., resigned from the Board due to potential conflicts of interest. Effective December 18, 2020, Prof. Richard W. Barker resigned due to other commitments.
- Independence Deficiency: Both departing directors were considered independent. Their resignations reduced the Board to five members, only two of whom are independent. Consequently, the Audit Committee now consists of only two independent members.
- Listing Non-Compliance: As of January 5, 2021, the Company is no longer in compliance with Nasdaq Listing Rules 5605(b)(1) (majority independent directors) and 5605(c)(2) (Audit Committee composition).
Guidance, Outlook, and Risks
Management Commentary and Plan: The Company is actively working to rectify the deficiencies by locating and appointing two new independent directors. At least one of the new appointees must qualify to serve on the Audit Committee.
Timeline and Deadlines:
- The Company has 45 days (until February 19, 2021) to submit a compliance plan to Nasdaq.
- If the plan is accepted, the Company may be granted up to an additional 180 days from January 5, 2021, to regain full compliance.
Risks and Contingencies: If Nasdaq does not accept the Company's plan, the Company retains the right to appeal the decision to a Nasdaq Hearings Panel before any change to the listing status occurs. The Company expresses confidence in filling the vacancies within the required timeframe.
Investor Verification Checklist
- Verify the current status of the search for two new independent directors.
- Confirm the submission date of the compliance plan to Nasdaq by the February 19, 2021 deadline.
- Monitor Nasdaq's acceptance of the compliance plan and any subsequent extension of the cure period.
- Review future filings for the appointment of new Board members and Audit Committee composition.